Literature DB >> 11397988

[Interferon beta-1b retinopathy during a treatment for multiple sclerosis].

S Sommer1, J C Sablon, M Zaoui, P Rozot, A Hosni.   

Abstract

Ocular adverse effects of interferon are described during the treatment of malignant diseases and chronic viral hepatitis with interferon alpha. At this time, there is no report of these effects during multiple sclerosis treatment with interferon beta-1b. The authors report a bilateral retinopathy during this treatment. The production of neutralizing antibodies during interferon beta-1b treatment leads to a decrease in diminution of therapeutic efficacy. When treatment failure occurs, neutralizing antibodies are to be tested.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397988

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  4 in total

1.  Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.

Authors:  Julia Button; Omar Al-Louzi; Andrew Lang; Pavan Bhargava; Scott D Newsome; Teresa Frohman; Laura J Balcer; Elliot M Frohman; Jerry Prince; Peter A Calabresi; Shiv Saidha
Journal:  Neurology       Date:  2017-01-11       Impact factor: 9.910

Review 2.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature.

Authors:  Lorenzo Gaetani; Paola S Menduno; Francesco Cometa; Maria Di Gregorio; Paola Sarchielli; Carlo Cagini; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2015-08-21       Impact factor: 4.849

Review 4.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.